Empagliflozin prevents doxorubicin-induced myocardial dysfunction

BACKGROUND: Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover, the EMPA-REG OUTCOME trial demonstrated a 14% reduction of major adverse cardiovascular events (MACE), a 38% reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabatino, Jolanda, De Rosa, Salvatore, Tammè, Laura, Iaconetti, Claudio, Sorrentino, Sabato, Polimeni, Alberto, Mignogna, Chiara, Amorosi, Andrea, Spaccarotella, Carmen, Yasuda, Masakazu, Indolfi, Ciro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229599/
https://www.ncbi.nlm.nih.gov/pubmed/32414364
http://dx.doi.org/10.1186/s12933-020-01040-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229599/
https://www.ncbi.nlm.nih.gov/pubmed/32414364
http://dx.doi.org/10.1186/s12933-020-01040-5

Ejemplares similares